Evidence map›Paper›PMID 28504717›Full record

ArticleOncogene2017

Fibulin-3 promotes muscle-invasive bladder cancer.

A L Han, B A Veeneman, L El-Sawy, K C Day, M L Day, S A Tomlins, E T Keller

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Application of Metabolic Reprogramming to Cancer Imaging and Diagnosis.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. METTL1-mClinical and translational medicine · 2021
    Article
  14. Small extracellular vesicles in cancer.Bioactive materials · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

A L HanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
B A VeenemanDepartment of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA.
L El-SawyDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
K C DayDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
M L DayDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
S A TomlinsDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
E T KellerDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · USBioSurfaces (United States) · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
6 · The paper itself

Abstract

Urothelial carcinoma is the most common type of bladder cancer and can be categorized as either non-muscle-invasive (Ta-T1) or muscle-invasive (⩾T2). The majority of bladder cancers are non-muscle-invasive at presentation; however, the recurrence rate for these tumors is high and a subset can progress to T2. In this study, we aimed to identify genes differentially expressed between T1 vs T2 bladder cancer to identify key regulators of bladder cancer progression and/or invasion. We performed RNA-Seq on T1 and T2 bladder cancer tissues and used publicly available bladder cancer profiling studies to prioritize differentially expressed genes for validation and functional assessment. This integrative approach nominated an extracellular matrix glycoprotein, fibulin-3 (FBLN3, also known as EFEMP1), as being highly expressed in T2 vs T1 bladder cancer and aggressive vs indolent disease. We confirmed the overexpression of fibulin-3 in ⩾T2 vs non-muscle-invasive bladder cancer (NMIBC) by quantitative reverse transcriptase-PCR. Consistent with these findings, fibulin-3 expression level correlated with the invasive ability of several bladder cancer cell lines and modulation of fibulin-3 expression directly affected invasion. Fibulin-3 knockdown in bladder cancer cells decreased the incidence of MIBCs in a murine orthotopic bladder cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5). Restoring IGFBP5 in these cells rescued their invasive and migratory potential. These results indicate that fibulin-3 serves as a pro-invasive factor in bladder cancer, which may be mediated through modulation of IGFBP5 expression. This also suggests fibulin-3 and IGFBP5 may have potential as biomarkers of aggressive bladder cancer or therapeutic targets.

Indexed as

AnimalsCell Line, TumorDisease ProgressionExtracellular Matrix ProteinsGene Knockdown TechniquesHeterograftsHumansInsulin-Like Growth Factor Binding Protein 5MaleMiceMice, Inbred NODMice, SCIDNeoplasm InvasivenessUrinary Bladder NeoplasmsEFEMP1 protein, humanExtracellular Matrix ProteinsInsulin-Like Growth Factor Binding Protein 5

Identifiers

PMID28504717
OpenAlexW2616305545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.